Coverage Decisions: The Hidden Valuation Key for Diagnostic AI

When you’re pricing a diagnostic AI, especially one fighting for reimbursement, its clinical efficacy and technological sophistication are just table stakes. For investors and analysts, the real valuation variable is the administrative record, the nitty-gritty of coverage decisions and coding guidance. If you don’t understand how payment policy dictates net revenue retention, you’re missing the entire investment thesis. Those bureaucratic details are everything.

The Coverage Framework: A Foundation for Diagnostic AI Valuation

For any diagnostic AI, a solid coverage framework is what makes commercialization possible. Without a clear way to get reimbursed, even the best, most-validated, FDA-cleared AI tool will stall out, failing to get adopted or generate real revenue. HeartFlow’s CT-derived FFR analysis (FFR-CT) is the classic case study. Its widespread coverage through local determinations and CPT codes is the foundation of its market viability and its valuation. Getting that kind of coverage signals to everyone, payers, doctors, investors, that the tech is medically necessary and clinically useful because it’s been through the wringer of clinical validation and health economic reviews. A weak or nonexistent coverage framework just screams regulatory risk and uncertainty, which kills a company’s valuation and its ability to raise money. It’s important to remember that for FFR, Medicare has no National Coverage Determination (NCD), so all the action is at the local level with Local Coverage Determinations (LCDs) and Local Coverage Articles (LCAs).

Working through the WPS Coding Record for FFR-Based Assets

Sure, widespread coverage is great, but the day-to-day reality of getting paid comes down to coding and payment policy. For something like HeartFlow’s FFR asset, the administrative record from a Medicare Administrative Contractor (MAC) like WPS Government Health Administrators is every bit as important as the clinical trial data. You have to read their specific coding guidance, documents like WPS A59813 version 6 and LCD L39913, to really get the billing and payment details for CT-derived FFR analysis. These docs spell out exactly which CPT codes to use, what the diagnostic criteria are, and how often you can bill for it. And don’t get comfortable, these guidelines aren’t set in stone. The changes coming on January 1, 2026, which are already outlined in those WPS documents, are a massive deal. An update like that can completely change the reimbursement picture, opening or closing markets and directly hitting a company’s net revenue retention. WPS Government Health Administrators LCD L39913 Any due diligence on an FFR asset that doesn’t tear these coding policies apart is worthless, because that’s what tells you about revenue predictability. This isn’t just about FFR, either. Competitors like Cleerly, with its plaque quantification tech, are under the exact same microscope for their own coding and coverage pathways. The MACs’ detailed administrative guidance simply determines a diagnostic AI company’s commercial success and how attractive it’s to investors.

Connecting Coverage Decisions to Valuation Inputs

If you’re a VC or run a family office, you need to get this: for diagnostic AI, payment policy is net revenue retention. You can’t put a real valuation on one of these assets without digging into its reimbursement stability and trajectory. The FDA CDRH clearance just tells you what conditions the device can be marketed for. That’s it. It doesn’t mean anyone will pay for it. Commercial potential gets realized only when FDA clearance, strong coverage, and good coding all line up. A broad FDA 510(k) clearance for an FFR-based tool sounds great, but if the coverage policies are tight or the CPT codes pay peanuts, the business opportunity is tiny. I’d much rather see a narrower clearance that’s tied to expansive coverage and well-paying codes, that’s a way better investment. That’s why every single coverage record, every local determination, and all the MAC-specific guidance belongs in the valuation file for any FFR-based asset. FDA 510(k) database A company that can show you a clear, stable reimbursement path has de-risked the investment significantly, and it gets a premium for it. It shows the product has clinical utility and, just as important, that the management team knows how to play the game in the healthcare payment world. You have to check if they’ve actually been talking to payers, if they have solid real-world evidence (RWE) to back up their coverage asks, and if they’ve secured favorable coding. When you see that alignment between the product, the regulatory clearance, and the payment policy, you know you’re looking at a mature, investable company.

Diligence Checklist for FFR-Based Assets

Because coverage and coding are so central, your diligence on any FFR-based AI asset needs its own specific checklist. This isn’t about the usual clinical validation scores or regulatory risk ratings. This is about digging into the messy details of payment policy.

Key elements of this diligence checklist include:

• Coverage Determination Review: What’s the scope and expected lifespan of the coverage? Check the local determinations for their specific conditions and limits, and remember CMS has no national coverage determination for FFR-CT.
• MAC-Specific Coding Guidance Analysis: Get your hands on all the relevant Local Coverage Determinations (LCDs) and Articles (LCAs) from the big MACs. For example, you need to read WPS Government Health Administrators’ docs WPS A59813 version 6 and LCD L39913 line-by-line. And watch the effective dates, that January 1, 2026 change is coming.
• CPT Code Assessment: Look at the assigned CPT codes (both Category I and Category III) for the diagnostic AI. What are the typical payment rates for those codes, and what’s the risk of a future reclassification or rate cut? CMS National Coverage Determinations
• Payer Penetration Depth: Getting Medicare coverage via local determinations is the first step. How far have they gotten with commercial payers? That’s what really opens up the market and the revenue.
• Administrative Record Evolution: What’s the history of coverage and coding look like? If it’s been a rollercoaster of changes, that’s a red flag for ongoing problems. You want stability.
• FDA CDRH Clearance Alignment: Put the FDA CDRH cleared indication set side-by-side with the current coverage policies. Do they match up? Any discrepancies mean you have a technology that’s cleared but won’t get paid for its full intended use.
• Health Economic Evidence: Go through the health economic data they show to payers. You need strong proof of cost-effectiveness and better patient outcomes to defend the coverage you have and get more in the future.

For these diagnostic AI companies, especially in a field like cardiac imaging, payment policy drives market momentum and investor confidence. The administrative record, which people often ignore in favor of the shiny tech or the clinical data, is the best tool you have for judging the real commercial viability and long-term value of these companies. If you’re going to invest in healthcare AI, you have to start with a policy-first valuation analysis, which means reading the coverage and coding documents yourself. It’s the only way to make an informed decision.